Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

DABIDOSE 110 MG CAPSULAS DURAS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/DABIDOSE 110 MG CAPSULAS DURAS EFG

Approved

STANDARD

DABIDOSE 110 MG CAPSULAS DURAS EFG

Ptr Pharma Consulting, Lda.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jun 24, 2024
Approval ID: f53c96e609696730
Company: Ptr Pharma Consulting, Lda.
Type: Standard

Approval Details

Approval Id: f53c96e609696730
Drug Cima Aemps Name: DABIDOSE 110 MG CAPSULAS DURAS EFG
Register Number: 89658
Holder Company Name: Ptr Pharma Consulting, Lda.
Marketing Company Name: Ptr Pharma Consulting, Lda.
Authorization Date: 2024-06-24
Dosage Form: CÁPSULA DURA
Dose: 110 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Ptr Pharma Consulting, Lda.

Active Ingredients

DABIGATRAN ETEXILATO MESILATO

126,83 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jun 24, 2024

Approval ID

f53c96e609696730

Type

Standard

Back to CIMA-AEMPS Approvals